The global Oral Proteins & Peptides Market , valued at US$7.35 billion in 2024, is forecasted to grow at a robust CAGR of 22.1%, reaching US$8.85 billion in 2025 and an impressive US$24.00 billion by ...

The global Oral Proteins & Peptides Market , valued at US$7.35 billion in 2024, is forecasted to grow at a robust CAGR of ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming ...

Days after Pfizer Inc. pulled the plug on its oral GLP-1 candidate danuglipron, Eli Lilly and Co. aired positive top-line data from the phase III trial called Achieve-1 testing orforglipron vs.

Abu Dhabi: Abu Dhabi-backed health-care investment company M42 has taken a stake in biotech startup Juvenescence, a UK-based ...

M42 and Juvenescence will collaborate in drug discovery to develop a pipeline of innovative medicines to advance the ...

Abu Dhabi’s state-backed health-care investment company M42 has taken a stake in biotech startup Juvenescence, a UK-based ...

Happily for investors, Pfizer is generating enough cash flow to cover its dividend. In 2024, it paid $9.5 billion in ...

Stocks like Pfizer, Amgen, Johnson & Johnson, and Eli Lilly & Co. were among others which opened lower after the US stock market opened on Wednesday. Pfizer Inc. shares are currently trading 2.56 ...

Pharmaceutical giant Pfizer sold its longtime San Diego campus to a life science-focused commercial real estate company in one of the largest deals of the past year. Pfizer sold the five ...